ANL · Adlai Nortye Group Ltd. · Documents
Market Cap
$674.57M
Shares
64.40M
Volume · Oct 23
64.93K
Avg daily vol (3M)
216.07K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Adlai Nortye Group Ltd. entered trial collaboration and supply agreements with Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035 alone and with cetuximab in a global Phase I trial; both will supply cetuximab at no cost. | 2026-10-15 | — | |
| 6-K | — | 2026-09-30 | — | |
| 6-K | — | 2026-09-30 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| 6-K | — | 2026-09-08 | — | |
| 6-K | — | 2026-08-26 | — | |
| 6-K | — | 2026-08-19 | — | |
| 6-K | — | 2026-08-14 | — | |
| 6-K | — | 2026-08-03 | — | |
| 6-K | — | 2026-07-17 | 2026-07-16 | |
| 6-K | — | 2026-04-16 | — | |
| 20-F | — | 2026-04-10 | 2025-12-31 | |
| 6-K | — | 2026-04-01 | — | |
| F-3 | — | 2026-03-10 | — | |
| 6-K | — | 2026-02-12 | — | |
| 6-K | — | 2026-02-03 | — | |
| 6-K | — | 2025-12-29 | — | |
| 6-K | — | 2025-12-29 | — | |
| 6-K | — | 2025-12-03 | — | |
| 6-K | — | 2025-10-22 | — | |
| 6-K | — | 2025-07-09 | — | |
| 6-K | — | 2025-05-30 | — | |
| 20-F/A | — | 2025-05-12 | 2024-12-31 | |
| 20-F | — | 2025-04-30 | 2024-12-31 | |
| 6-K | — | 2025-02-14 | — | |
| 20-F/A | — | 2025-02-14 | 2023-12-31 | |
| 6-K | — | 2024-12-31 | — | |
| 6-K | — | 2024-08-08 | — | |
| 6-K | — | 2024-07-03 | — | |
| 6-K | — | 2024-06-27 | — | |
| 6-K | — | 2024-05-24 | 2024-05-23 | |
| 20-F | — | 2024-04-19 | 2023-12-31 | |
| 6-K | — | 2024-04-02 | — | |
| F-1 | — | 2023-07-27 | — |
Showing 1–34 of 34 filings